PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för GDC-0623. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

7 hits

Bibliografisk träff 2020-04-02

Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line.

Byrne CE, Astete CE, Vaithiyanathan M, Melvin AT, Moradipour M, Rankin SE, Knutson BL, Sabliov CM, Martin EC.

Nanomedicine (Lond) · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.2217/nnm-2020-0010

Bibliografisk träff 2019-10-03

Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes.

Park E, Rawson S, Li K, Kim BW, Ficarro SB, Pino GG, Sharif H, Marto JA, Jeon H, Eck MJ.

Nature · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/s41586-019-1660-y

Bibliografisk träff 2016-07-15

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.

Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, Koomen JM, Haura EB.

Mol Cancer Res · research-article; journal article · DOI 10.1158/1541-7786.mcr-15-0506

Bibliografisk träff 2015-10-05

Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor.

Takahashi RH, Ma S, Robinson SJ, Yue Q, Choo EF, Khojasteh SC.

Drug Metab Dispos · journal article · DOI 10.1124/dmd.115.067181

Bibliografisk träff 2015-08-05

The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.

Zaanan A, Okamoto K, Kawakami H, Khazaie K, Huang S, Sinicrope FA.

J Biol Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.m115.657833

Bibliografisk träff 2014-08-15

Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.

Robarge KD, Lee W, Eigenbrot C, Ultsch M, Wiesmann C, Heald R, Price S, Hewitt J, Jackson P, Savy P, Burton B, Choo EF, Pang J, Boggs J, Yang A, Yang X, Baumgardner M.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2014.08.008

Bibliografisk träff 2013-08-11

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.

Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, Hewitt JF, Zak M, Peck A, Orr C, Merchant M, Hoeflich KP, Chan J, Luoh SM, Anderson DJ, Ludlam MJ, Wiesmann C, Ultsch M, Friedman LS, Malek S, Belvin M.

Nature · comparative study; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/nature12441